SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 12B-25
Commission File Number 0-50956
NOTIFICATION OF LATE FILING
(Check One): |_| Form 10-K |_| Form 20-F |_| Form 11-K |X| Form 10-Q
For Period Ended: January 31, 2006
--------------------------
|_| Transition Report on Form 10-K
|_| Transition Report on Form 20-F
|_| Transition Report on Form 11-K
|_| Transition Report on Form 10-Q
|_| Transition Report on Form N-SAR
For the Transition Period Ended:
------------------------------
Read attached instruction sheet before preparing form. Please print or
type. Nothing in this form shall be construed to imply that the
Commission has verified any information
contained herein.
If the notification relates to a portion of the filing checked above,
identify the Item(s) to which the notification relates:_________________________
PART I - REGISTRANT INFORMATION
Full name of registrant: Pharma-Bio Serv, Inc.
Former name if applicable: Lawrence Consulting Group, Inc.
Address of principal executive office:
373 Mendez Vigo, Suite 110
Dorado, Puerto Rico 00646
PART II. RULE 12B-25 (B) AND (C)
If the subject report could not be filed without unreasonable effort or expense
and the registrant seeks relief pursuant to Rule 12b-25(b), the following should
be completed. (Check appropriate box.)
|X| (a) The reasons described in reasonable detail in Part III of this form
could not be eliminated without unreasonable effort or expense;
|X| (b) The subject annual report, semi-annual report, transition report on Form
10-K, 20-F, 11-K or Form N-SAR, or portion thereof will be filed on or before
the 15th calendar day following the prescribed due date; or the subject
quarterly report or transition report on Form 10-Q, or portion thereof will be
filed on or before the fifth calendar day following the prescribed due date; and
|_| (c) The accountant's statement or other exhibit required by Rule 12b-25(c)
has been attached if applicable.
PART III. NARRATIVE
State below in reasonable detail the reasons why Form 10-K, 11-K, 20-F, 10-Q,
N-SAR or the transition report portion thereof could not be filed within the
prescribed time period.
As a result of delays in developing and verifying data necessary to complete the
financial statement disclosure, the Form 10-QSB for the quarter ended January
31, 2006 could not be filed on time without unreasonable effort and expense.
PART IV. OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to this
notification
Elizabeth Plaza (787) 278-0290
--------------------------- ---------------------------
(Name) (Area code) (Telephone number)
(2) Have all other periodic reports required under Section 13 or 15(d) of the
Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of
1940 during the preceding 12 months or for such shorter period that the
registrant was required to file such report(s) been filed? If the answer is no,
identify report(s).
|X| Yes |_| No
(3) Is it anticipated that any significant change in results of operations
from the corresponding period for the last fiscal year will be reflected by the
earnings statements to be included in the subject report or portion thereof?
|X| Yes | | No
If so: attach an explanation of the anticipated change, both narratively
and quantitatively, and, if appropriate, state the reasons why a reasonable
estimate of the results cannot be made.
In January 2006, the registrant, then known as Lawrence Consulting Group,
Inc., acquired Plaza Consulting Group, Inc. in a transaction which is accounted
for as a reverse acquisition, with Plaza Consulting Group being treated as the
acquiring party for accounting purposes. Accordingly, the financial statements
for the prior period will reflect the operations of Plaza Consulting Group.
PHARMA-BIO SERV, INC.
---------------------
(Name of registrant as specified in charter)
Has caused this notification to be signed on its behalf by the undersigned
thereunto duly authorized.
Date March 17, 2006 By /s/ Elizabeth Plaza
---------------------------
President and Chief Executive Officer